Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
EyeCon 2025: Adopting an interventional glaucoma mindset with Oluwatosin U. Smith, MD | Ophthalmology Times
At this year’s EyeCon meeting, Oluwatosin U. Smith, MD, of the Glaucoma Associates of Texas, reflected on her dual role—both as an educator and a leader in its development—while delivering a focused presentation on the current state of glaucoma care.…
EyeCon 2025 celebrates Visionary in Eye Care Resident Award winners | Ophthalmology Times
The recipients of this year’s Visionary in Eye Care Resident Recognition Awards were revealed at the Ophthalmology Times and Optometry Times EyeCon® 2025 conference, held September 26 and 27 at the Margaritaville Hollywood Beach Resort, in Hollywood, Florida. The program…
Q&A: Boris Stanzel on the use of methotrexate in PVR cases | Ophthalmology Times
Photo of Boris Stanzel, MD, at the 2025 EURETINA meeting Professor Boris Stanzel, MD, presented research on methotrexate’s use in PVR retinal detachment surgery at the 2025 EURETINA congress, which was held in Paris, France. The study of 20 patients…
The European Commission grants marketing authorization for EYLUXVI | Ophthalmology Times
(Image Credit: AdobeStock) The European Commission (EC) has granted marketing authorization for EYLUXVI (ALT-L9), an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.1 EYLUXVI is Alteogen’s second approved biosimilar; the other approval is the company’s trastuzumab (Herceptin) biosimilar. Alteogen received a…
OKYO Pharma details next clinical stage of urcosimod development | Ophthalmology Times
OKYO Pharma has announced its plans for the next stage of clinical development of urcosimod (formerly OK-101), its lead drug candidate to treat neuropathic corneal pain (NCP). NCP is a condition that causes severe pain and sensitivity of the eyes, face,…
Q&A: Anat Loewenstein recaps the 2025 EURETINA meeting | Ophthalmology Times
Photo of Anat Loewenstein at EURETINA 2025 The 25th EURETINA conference was a landmark event, attracting 11,000 participants from around the world. Anat Loewenstein, MD, the 2025 The president of EURETINA, highlighted the meeting’s comprehensive scientific program, featuring sessions on…
Care of newly diagnosed POAG impacted by patient wealth, area of residence | Ophthalmology Times
(Image credit: AdobeStock/masud) The results of a new cohort study found that newly diagnosed primary open-angle glaucoma (POAG) in patients who were in the lowest wealth quartile was “substantially” less likely to reach the recommended reduction and the patients “considerably”…
Q&A: Robyn Guymer highlights risk factors of intermediate AMD | Ophthalmology Times
Photo of Robyn Guymer at EURETINA 2025 in Paris, France Professor Robyn Guymer from the University of Melbourne discussed intermediate age-related macular degeneration (AMD) at the 2025 EURETINA meeting. She explored risk factors for disease progression, focusing on optical coherence…
Part 6: What if? Curing any eye disease with the snap of your finger | Ophthalmology Times
In celebration of Ophthalmology Times‘ 50th anniversary, we asked leading experts in the field, in a perfect world, if they had the ability to cure one eye disease or condition in the snap of their finger, what they would choose…
Virtual Vision Health and VirtuaLens enter partnership to accelerate virtual reality in eyecare | Ophthalmology Times
(Image credit: AdobeStock/matrosovv) Virtual Vision Health and VirtuaLens have entered a strategic partnership to expand access to and accelerate adoption of VR screening and patient education tools. The Virtual Eye VR platform from Virtual Vision Health offers an untethered, all-in-one…